Equities analysts expect BioXcel Therapeutics Inc (NASDAQ:BTAI) to post ($0.52) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for BioXcel Therapeutics’ earnings. BioXcel Therapeutics posted earnings per share of ($0.19) during the same quarter last year, which suggests a negative year-over-year growth rate of 173.7%. The company is expected to announce its next quarterly earnings report on Wednesday, August 14th.
On average, analysts expect that BioXcel Therapeutics will report full year earnings of ($2.19) per share for the current financial year. For the next year, analysts forecast that the company will report earnings of ($3.01) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow BioXcel Therapeutics.
BioXcel Therapeutics (NASDAQ:BTAI) last issued its earnings results on Tuesday, May 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.02.
Several brokerages have recently issued reports on BTAI. HC Wainwright reaffirmed a “buy” rating on shares of Zomedica Pharmaceuticals in a report on Wednesday, June 5th. Zacks Investment Research raised GCP Applied Technologies from a “sell” rating to a “hold” rating in a report on Friday, May 31st. Finally, ValuEngine cut Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, July 8th.
Shares of BTAI stock traded up $0.22 during trading hours on Friday, hitting $10.54. The stock had a trading volume of 9,684 shares, compared to its average volume of 69,594. BioXcel Therapeutics has a one year low of $2.41 and a one year high of $12.00. The company has a quick ratio of 5.59, a current ratio of 5.59 and a debt-to-equity ratio of 0.04. The business has a 50-day simple moving average of $10.86. The stock has a market capitalization of $165.12 million, a PE ratio of -7.98 and a beta of 3.03.
An institutional investor recently bought a new position in BioXcel Therapeutics stock. Creative Planning purchased a new position in BioXcel Therapeutics Inc (NASDAQ:BTAI) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned approximately 0.20% of BioXcel Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by hedge funds and other institutional investors.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.